PTC Therapeutics Inc introduces PTC Pinpoint Direct-CP Spectrum, a no-charge, patient-initiated testing program in the United States for individuals who have symptoms consistent with, or a diagnosis of, cerebral palsy (CP) with no evidence of brain injury.
The Duchenne community launches DuchenneXchange V2.0, an enhanced version of its collaborative digital platform and mobile app.
A $7.8-million grant from the National Institute of Neurological Disorders and Stroke, one of the National Institutes of Health (NIH) is funding a collaboration between University of Louisville and Medtronic on an epidural stimulation project for people with spinal cord injury.
Researchers at Indiana University School of Medicine have successfully reprogrammed a glial cell type in the central nervous system into new neurons to promote recovery after spinal cord injury–revealing an untapped potential to leverage the cell for regenerative medicine.
Read More
A review of nearly 28,000 emergency department records suggests that less than 2% of patients diagnosed with COVID-19 suffered an ischemic stroke but those who did had an increased risk of requiring long-term care after hospital discharge.
Read More
Parent Project Muscular Dystrophy (PPMD) has awarded the University of Florida (UF) Wellstone Muscular Dystrophy Cooperative Center a grant for $348,891 for its research project to help understand and improve gene therapy for Duchenne.
Read More
Parent Project Muscular Dystrophy (PPMD) and Duchenne UK announce Professor Kanneboyina Nagaraju at Binghamton, the State University of New York, as the recipient of their Joint Research Grant Call of 2020.
Read More
Northwestern University scientists have identified the first compound that eliminates the ongoing degeneration of upper motor neurons that become diseased and are a key contributor to ALS (amyotrophic lateral sclerosis). Their study was published recently in Clinical and Translational Medicine.
Read More
The US Food and Drug Administration granted approval for Amondys 45 (casimersen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
Read More
Revance Therapeutics Inc announces positive topline data from its JUNIPER Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical trial of its investigational drug candidate DaxibotulinumtoxinA for Injection for the treatment of adults with moderate to severe upper limb spasticity.
Read More
Intravenous injection of bone marrow derived stem cells (MSCs) in patients with spinal cord injuries led to significant improvement in motor functions, researchers from Yale University and Japan report in the Journal of Clinical Neurology and Neurosurgery.
Read More
The Christopher & Dana Reeve Foundation has published the fifth edition of the Paralysis Resource Guide, a free 410-page book that helps families understand new spinal cord injuries and supports individuals as they pursue healthy, fulfilling lives.
Read More
Genetic mutations which occur naturally during the earliest stages of an embryo’s development can cause the severe birth defect spina bifida, University College London scientists suggest, in Nature Communications.
Read More
The Muscular Dystrophy Association (MDA) launches its St Patrick’s Day fundraising program, the 39th annual MDA Shamrocks campaign.
Read More
The Christopher & Dana Reeve Foundation, in partnership with Shepherd Center, introduce a new video series: Cultivating Resilience After Spinal Cord Injury Trauma.
Read More
Matthew Walzer, who was born with cerebral palsy, has managed to master various motor skills, but tying shoes was not one of them. So he wrote a letter to Nike for help with making shoewear more accessible. The company responded with its new GOFlyEase line of slip-on sneakers.
Read More
The International Spinal Research Trust (ISRT) and the Christopher & Dana Reeve Foundation (Reeve Foundation) announce a joint approach to their research strategies with a focus on accelerating the progress of therapies and their delivery to people living with paralysis.
Read More
Parent Project Muscular Dystrophy (PPMD) announces a $100,000 sponsorship from the Duchenne Research Fund as part of PPMD’s new Brain Initiative.
Read More